|
 
- 现金
- 20661 元
- 精华
- 7
- 帖子
- 12793
- 注册时间
- 2013-12-29
- 最后登录
- 2024-11-3
|
本帖最后由 newchinabok 于 2018-8-10 20:06 编辑
Assembly Biosciences Announces Second Quarter 2018 Financial Results
August 8, 2018 at 4:05 PM EDT
PDF Version
- ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Initial Data Continues to be Anticipated in H1 2019
- Strong Balance Sheet Provides Significant Runway
SAN FRANCISCO and INDIANAPOLIS, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today reported financial results for the second quarter ended June 30, 2018.
“Based on the positive Phase 1b data for ABI-H0731 that we reported at EASL 2018 in April, we have initiated enrollment in our Phase 2a viral antigen and viral load trials in HBV patients and have raised approximately $155 million in an oversubscribed public stock offering. This gives us substantial resources to advance our pipeline, including completion of these Phase 2a trials and the introduction of ABI-2158 into the clinic, which is planned for later this year,” said Derek Small, President and Chief Executive Officer. “We also were pleased that ABI-H0731 received Fast Track Designation from the FDA, which allows us to work closely with the agency to bring this new therapeutic candidate to HBV patients as quickly as possible.”
Recent Highlights
Assembly began enrolling patients in two Phase 2a proof of concept studies evaluating ABI-H0731, the Company’s lead core inhibitor targeting HBV. Initial data from both studies are expected in the first half of 2019. ABI-H0731 was also granted Fast Track Designation by the U.S. Food and Drug Administration (FDA).
On July 16, 2018, Assembly announced the closing of an underwritten public offering of 4,600,000 shares of common stock at a public offering price of $36.00 per share, which includes the full exercise of the underwriters’ option to purchase additional shares. Net proceeds to Assembly from this offering were approximately $155 million.
Assembly hosted its first Research and Development Day in New York on June 20, 2018. Two key opinion leaders highlighted the need for new and curative treatments for the millions of patients living with HBV. Company management also presented the development plans for ABI-H0731 and the second generation core inhibitor candidate, ABI-H2158. The presentation and recorded replay of the event can be accessed in the Investors section of the Company’s website.
Anticipated Milestones and Events
ABI-H0731
Initial Phase 2a data expected in the first half of 2019
ABI-2158
Phase 1a clinical trial initiation in healthy volunteers expected in the fourth quarter of 2018
Upcoming events
Baird Global Healthcare Conference in New York, September 5-6, 2018
Morgan Stanley Global Healthcare Conference in New York, September 12-14, 2018
Second Quarter Financial Results
|
|
发表于 2018-8-10 20:02
